Zymeworks appoints Adam Schayowitz as Acting Chief Development Officer

Zymeworks (ZYME) appointed Adam Schayowitz as Acting Chief Development Officer. In this role, Schayowitz will work closely with the Zymeworks R&D and Business Development teams to advance the company’s portfolio of nominated product candidates, while also supporting Zymeworks’ strategy to integrate partnerships and collaborations into the current wholly-owned portfolio. As this is a part-time role, Schayowitz will also continue to serve as an Operating Partner at EcoR1 Capital, a biotech-focused investment advisory firm which invests in companies at all stages of research and development. Prior to joining EcoR1 as an Operating Partner, he was a VP at Pfizer Oncology holding various development leadership roles across breast cancer, prostate cancer, colorectal cancer and melanoma, ultimately culminating in serving as Head of Product Development Teams. Prior to Pfizer, Schayowitz led the development of Zejula at Tesaro and was a member of the Medical Affairs leadership team at Algeta supporting the commercialization of Xofigo. He is currently a Board Member at Terremoto Biosciences and serves as a Board Observer for Aktis Oncology.